Leuprorelin - Tolmar

Drug Profile

Leuprorelin - Tolmar

Alternative Names: Eligard; LA 2575; Leuprogel®; SOT-375; SOU 375

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator QLT USA
  • Developer Tolmar
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer
  • Phase III Precocious puberty
  • Discontinued Endometriosis

Most Recent Events

  • 05 Sep 2018 Tolmar completes a phase III trial in Precocious puberty (In children) in Canada, Chile, Mexico, Argentina, New Zealand (SC) (NCT02452931)
  • 19 Feb 2018 TOLMAR Australia has been acquired by Mundipharma (China) Pharmaceutical
  • 15 May 2017 Pooled pharmacokinetics data from four pivotal studies in Prostate cancer presented at the 112th Annual American Urological Association Meeting in Boston (AUA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top